PHA and Cure HHT – Murali M. Chakinala, M.D. discusses the importance of recognizing the signs and symptoms of Pulmonary Hypertension (PH) and Hereditary Hemorrhagic Telangiectasia (HHT), and the importance of early diagnosis as well as disease management. Approximately 15-20% of people with HHT either have or are developing Pulmonary Hypertension (PH). A few common…

In March 2020, Cure HHT was 1 of 30 organizations selected to participate in the Chan Zuckerberg Initiative (also known as CZI) Rare is One Project. This ambitious project is lifting up the work that patient communities are doing to accelerate research and drive progress against rare diseases. The CZI Rare as One project is…

El Dr. Marcelo Serra, Director de la Unidad de HHT del Hospital Italiano de Buenos Aires brinda información sobre el tratamiento farmacológico no quirúrgico del sangrado nasal en HHT. También revisó las recomendaciones de las nuevas Directrices internacionales de HHT para el tratamiento de las hemorragias nasales. Dada la alta frecuencia de epistaxis en HHT…

Dr. Marie Faughnan, Director, Toronto HHT Centre of Excellence, discusses Brain Vascular Malformations (VMs) as they relate to HHT. Dr. Faughnan is a renowned HHT specialist and will walk the audience through a comprehensive overview of what a brain VM diagnosis means for HHT patients and the various treatment options available. In addition, Dr. Faughnan…

Liver involvement occurs in approximately 75% of people with HHT. While many people are asymptomatic, the complications associated with liver involvement have historically been under diagnosed. These complications include arterioportal shunting leading to portal hypertension and arteriosystemic shunting leading to high output cardiac failure (HOCF). HOCF occurs much more frequently than has previously been considered.…